On the other hand, selpercatinib has been shown to produce a significant increase in progression-free and treatment failure-free survival compared with standard treatments (i.e. cabozantinib or vandetanib) in patients with RET-mutant MTC (4). This evidence concerns the gene RET and medullary thyroid gland carcinoma.